Pasithea Therapeutics Corp. (KTTAW) Cash & Equivalents (2020 - 2026)

Pasithea Therapeutics has disclosed Cash & Equivalents across 7 years of filings, most recently posting $45.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 533.22% year-over-year to $45.7 million; the TTM figure through Jun 2026 stood at $45.7 million (up 533.22% YoY), while the FY2025 annual figure was $55.2 million, up 697.37% from the prior year.
• Cash & Equivalents came in at $45.7 million for Q2 2026 at Pasithea Therapeutics, down from $50.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $55.2 million in Q4 2025 to a low of $4.1 million in Q3 2025.
• Average Cash & Equivalents over 5 years is $26.1 million, with a median of $23.1 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 69.98% in 2024 and soared 843.6% in 2026.
• Over 5 years, Cash & Equivalents stood at $33.1 million in 2022, then tumbled by 50.64% to $16.3 million in 2023, then slumped by 57.61% to $6.9 million in 2024, then soared by 697.37% to $55.2 million in 2025, then decreased by 17.21% to $45.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $45.7 million in Q2 2026, $50.4 million in Q1 2026, and $55.2 million in Q4 2025.